The Company expects to exceed 2022 full-year guidance for net product revenues
- Preliminary net product revenues for the fourth quarter and full-year 2022 are expected to total $235.5 million and $843.3 million, respectively
- Preliminary year-end 2022 cash balance of approximately $2.0 billion
https://finance.yahoo.com/news/sarepta-therapeutics-reports-preliminary-fourth-182800422.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.